Background: COVID-19 is a condition that can proceed in a broad spectrum from asymptomatic moderate sickness to severe lung disease. Hepatic harm in COVID-19 may arise owing to the direct cytopathic action of the virus, uncontrolled immunological response, hypoxia related to pneumonia, and the medications used in therapy. In the literature, the rate of rise in blood transaminase levels of patients hospitalized with COVID-19 was determined to be 37.5%. Also, rise in serum transaminase levels in COVID-19 patients has been shown to be related with higher mortality in the literature. Favipiravir is a ribonucleic acid (RNA)-dependent RNA polymerase (RdRP) inhibitor antiviral drug used in the treatment of coronavirus disease-2019 (COVID-19)
Aims: In this study, we investigated the changes in serum transaminase levels of patients who were hospitalized with the diagnosis of COVID-19 and underwent favipiravir therapy.
Materials and methods: case-control research was done. It was done in a multi-hospital of Baghdad city over the period from November 1, 2020, to August 1, 2021. All patients in this study were hospitalized patients with polymerase chain reaction identified Coronavirus illness 2019 (severe cases) according to Iraqi criteria and supervision of a professional.
Results: case-control research was done. It was done in a multi-hospital of Baghdad city over the period from November 1, 2020, to August 1, 2021. All patients in this study were hospitalized patients with polymerase chain reaction identified Coronavirus illness 2019 (severe cases) according to Iraqi criteria and supervision of a professional.
(FULL ARTICLE LINK) Read more ...
2021/12/21
|
|
|
